134 related articles for article (PubMed ID: 28408000)
1. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System.
Coyle D; Ko YJ; Coyle K; Saluja R; Shah K; Lien K; Lam H; Chan KK
Value Health; 2017 Apr; 20(4):586-592. PubMed ID: 28408000
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
10. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Carrato A; García P; López R; Macarulla T; Rivera F; Sastre J; Gostkorzewicz J; Benedit P; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):579-89. PubMed ID: 25991037
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.
Chan K; Shah K; Lien K; Coyle D; Lam H; Ko YJ
PLoS One; 2014; 9(10):e108749. PubMed ID: 25286060
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
Saito S; Muneoka Y; Ishikawa T; Akazawa K
Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
Tam VC; Ko YJ; Mittmann N; Cheung MC; Kumar K; Hassan S; Chan KK
Curr Oncol; 2013 Apr; 20(2):e90-e106. PubMed ID: 23559890
[TBL] [Abstract][Full Text] [Related]
20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]